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Antigen presentationCell penetrating peptides (CPP) represent a novel approach to facilitate cytoplasmic delivery of
macromolecules. The DNA binding domain of Drosophila Antennapedia contains 60 amino acids and consists
of 3 α-helices, with internalizing activity mapped to a 16-amino acid peptide penetratin (Antp) within the
third α-helix. Here, we report on the use of penetratin to deliver a multiple antigen peptide (MAP)
incorporating the immunodominant CD8 epitope of ovalbumin, SIINFEKL (MAPOVACD8). We demonstrate
that penetratin linked to the MAPOVACD8 construct either by a disulﬁde (SS) or thioether (SC) linkage
promotes the uptake, cross presentation and subsequent in vivo proliferation and generation of OVACD8
(SIINFEKL)-speciﬁc T cells. The MAPOVACD8 construct without penetratin is not presented by MHC class I
molecules nor does it generate an in vivo IFN-γ response in C57BL/6 mice. Moreover, we clearly deﬁne the
uptake and intracellular processing pathways of AntpMAPOVACD8 SS and SC revealing the majority of
AntpMAPOVACD8 is taken up by DC via an endocytic, proteasome and tapasin independent mechanism. We
also show that the uptake mechanism of AntpMAPOVACD8 is dose dependent and uptake or intracellular
processing is not altered by the type of chemical linkage.IKIWFQNRRMKWKK; CPP, cell
ACD8, immunodominant CD8
; SC, thioether linkage
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Fundamental for an effective vaccine is the delivery of immuno-
genic antigens to antigen-presenting cells (APC), ensuing processing
and presentation, and induction of an immune response [1,2].
Vaccination with peptides incorporating cytotoxic T lymphocyte
(CTL) epitopes has proven limited due to the failure for exogenous
antigens to be presented efﬁciently to T cells [2]. There are now
several strategies to promote the delivery of antigens to APC, with one
such method utilizing the unique translocating properties of cell
penetrating peptides (CPP) [3–7].
CPP offer a unique approach for the transport of peptides and
proteins into the cytoplasm of cells. The TAT protein from human
immunodeﬁciency virus, penetratin (Antp) from Drosophila Antenna-
pedia and the VP22 protein from herpes simplex virus are some of the
CPP which have been investigated in vaccine studies for delivery oftumor associated antigens to APC and for the use as a non-viral gene
delivery vehicle in DNA vaccines, producing promising results [4,8–10].
It is now clear to overcome some of the limitations of previous
peptide vaccines it is necessary to ﬁrstly, incorporate both CD8 T
cytotoxic (Tc) and CD4 T helper (Th) epitopes to promote the
generation of long term immunity and secondly major histocompat-
ibility complex (MHC) restriction must be considered to allow
application to the wider population [11,12].
Lu et al. utilized a recombinant protein incorporating the 9-mer
TAT peptide linked to multiple epitopes from the protein ovalbumin
(OVA) to demonstrate that immunization with multiepitope vaccines
incorporating TAT-OVA CD8-CD4 T cell epitopes and the adjuvant CpG
results in strong CTL and Th responses and generates an anti-tumor
response [13]. Similarly, Dakappagari et al. (2005) utilized a multi-
epitope peptide incorporating the CPP Pep-1 with three HLA-A2
restricted epitopes from Her-2/neu to prime CTL responses in mice
[14]. However in both cases either furin sensitive (RVKR) sequences
or arginine spacers were required to facilitate cleavage for processing
and presentation [13,14].
Due to chemical synthesis restraints on the length of linear
peptides, the number of Tc and Th epitopes that can be incorporated is
limited. Branched multiple antigen peptides (MAP) may help
overcome such limitations by allowing the delivery of numerous
tumor antigens. Yet there is now evidence that as a result of varying
antigen uptake mechanisms and/or differential resistance to the
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branched constructs presented to T cells are processed differently to
those derived from linear peptides [11,15]. Thus far there have been
no reports on the use of CPP to transport branchedMAP incorporating
CTL epitopes into APC.
Herein we report on the uptake, processing and presentation
pathways of a novel asymmetric 4 branchedMAP incorporating the H-
2Kb CD8 eight-mer epitope SIINFEKL, from the ovalbumin protein. We
reveal that linkage of a MAPOVACD8 construct to Antp via a disulﬁde
(SS) or thioether (SC) linkage is endocytosed via phagocytosis or
macropinocytosis by dendritic cells in an ATP-dependent manner and
processed in a proteasome and tapasin (TAP) independent pathway.
Moreover AntpMAPOVACD8 constructs generate potent in vivo
proliferation and killing and induce antigen-speciﬁc IFN-γ secreting
T cell responses superior to MAPOVACD8 construct alone.
2. Materials and methods
2.1. Mice and immunizations
C57BL/6, OT-I and OT-II mice, aged 6–10 weeks, were obtained
fromWalter and Eliza Hall Institute (Vic., Australia) and housed in the
animal facilities of the Burnet Institute or RMIT University (Victoria,
Australia). For immunization experiments mice were injected three
times on days 0, 10 and 17 intradermally (i.d.) at the base of tail with
100 µg peptide. CpG-ODN 1668 (5′-TCC ATG ACG TTC CTG ATG CT-3′)
with phosphorothioate linkages was synthesized by Geneworks
(Adelaide, Australia) and dissolved in sterile PBS and stored at
−20 °C. For tumor protection experiments mice were immunized
with 50 µg CpG i.d.
2.2. Peptides
Peptides were synthesized by Genescript Corporation (San Fran-
cisco, USA) and purity determined by mass spectrometry. OVACD8
(SIINFEKL) is the ovalbumin H-2Kb CTL epitope 8-mer peptide and
penetratin (Antp) is a 16 amino acid (RQIKIWFQNRRMKWKK)
Antennapedia peptide. MAPOVACD8 is a 4 asymmetric branched
(C-Terminal) MAP synthesized using the (Fmoc)4Lys2LysCysβAla
(Free Cysteine) resin with SIINFEKLKGKGKGKGKG on each branch.
The conjugation of MAPOVACD8 to Antp was performed using a
disulﬁde (SS) bond or a thioether (SCH2CO (SC)) bond (Fig. 1) as
described below.
For synthesis of the disulphide-linked MAP cysteine modiﬁed
MAPOVACD8 (0.5 ml, 6.2 mg/ml) in water was reacted with 5,5′-
dithiobis-(2-nitrobenzoic acid, DTNB) (0.2 ml, 7.5 mg/ml) in 0.1 M
phosphate buffer, pH 7.5 for 3–4 h. The yellow solution was dialysed
into PBS overnight. The MAPOVACD8 incorporating the activated
disulphide was reacted with Antp peptide (0.2 ml, 5 mg/ml)
incorporating a Cysteine at the C-terminal. After 3–4 h the mixture
was dialysed into PBS overnight. The concentration of MAPOVACD8
was determined spectrometrically based on the DTNB anion released
(ε412=13,600 M−1 cm−1). The thioether conjugated MAP was
synthesized by reacting MAPOVACD8 (0.5 ml, 6.2 mg/ml) in 0.1 M
phosphate buffer, pH 7.5 with the N-terminal bromoacetyl-modiﬁed
Antp (0.2 ml, 5 mg/ml) for 16 h. The mixture was dialysed overnight
to remove free Antp.
The cytotoxicity of the complexes was measured using the lactate
dehydrogenase assay [16]. Antp complexes showed no signiﬁcant
cytotoxicity at concentrations of up to 25 µM (not shown).
2.3. Generation of bone marrow derived dendritic cells (BMDC)
Bone marrow cells from C57BL/6 female mice were collected by
ﬂushing the tibias of hind legs and treated with ACK lysis buffer
(0.15 M NH4Cl, 1 mM KHCO3 and 0.1 mM Na2EDTA) to lyse erythro-cytes. Cells were washed and cultured at 5×105 cells/ml in 24 well
plates with complete RPMI-1640 medium 10% (v/v) heat inactivated
fetal calf serum, 4 mM L-glutamine, 100 U/ml penicillin, 100 µg/ml
streptomycin sulphate and 100 µM β-mercaptoethanol) with 10 ng/
ml each of recombinant mouse granulocyte macrophage colony-
stimulating factor (GM-CSF) and interleukin- 4 (IL-4) (Pharmingen,
San Diego, CA). At day 6 cells were N80% CD11c+ which was
conﬁrmed by ﬂow cytometry (data not shown).
2.4. Stimulation of lacZ-inducible ovalbumin-speciﬁc T cell hybrid
The B3Z mouse T cell hybridoma line contains a gene construct of
Escherichia coli lacZ reporter gene linked to the nuclear factor of
activated T cells. Recognition of the OVACD8 peptide in the context of
class I by the T cell receptor (TCR) results in activation of the enzyme
and conversion of the chromogenic substrate that can bemeasured by
absorbance spectrophotometry [17]. DC, EL-4 and RMA-S cells
(2×105 cells) were pulsed with peptides at 5, 25 and 50 µM in 96-
well microtitre plates (Falcon, BD Biosciences, North Ryde, Australia)
for 24 h at 37 °C. Cells were thenwashed and 105 B3Z cells were added
for 18 h at 37 °C. The next day cells were washed with sterile PBS and
incubated with chlorophenol red-β-galactoside (Calbiochem, San
Diego, CA) (100 µM 2-ME, 9 mM MgCl2, 0.125% NP40, 0.15 mM
chlorophenol red-β-galactoside). After 4 h incubation at 37 °C the
absorbance was read at 560 nm.
2.5. Enzyme-linked immunosorbent spot-forming cell assay (ELISpot)
Splenocytes from immunized C57BL/6 mice were isolated and
assessed by ELISpot for antigen-speciﬁc IFN-γ secretion. MultiScreen
ﬁlter plates (Millipore, Billerica, MA)were coated with 5 µg/mL of anti-
mouse IFN-γ antibody (AN18) (Mabtech, Stockholm, Sweden) over-
night at 4 °C. Plates were washed six times with sterile PBS and blocked
with 200 µl complete RPMImedia for 2 h at 37 °C. Spleen cells (5×105/
well) from immunized mice were added to wells in 100 µl of complete
medium and incubated with 20 µg/ml recall antigens for 18 h.
Concanavalin A (1 µg/ml) or cells alone were used as positive and
negative controls, respectively. Triplicate wells were set up for each
condition. Cells were discarded after washing (PBS) and 1 µg/mL
biotinylated anti-mouse IFN-γ antibody (Mabtech)was added for 2 h at
room temperature. The plates were washed with PBS and 1 µg/ml
streptavidin–alkaline phosphatase (Mabtech) added at room temper-
ature for 2 h. Spots of activity were detected using a colorimetric AP-
conjugate substrate kit (Bio-Rad Laboratories, Foster City, CA). Cytokine
spots were counted with an AID ELISpot Reader system (Autoimmun
Diagnostika GmbH, Strassberg, Germany). Data is presented as mean
spot-forming units (SFU) per 5×105 cells±standard error of the mean
(SEM).
2.6. Tumor protection
Groups of C57BL/6 mice (n=8) were immunized i.d. with PBS,
AntpMAPOVACD8 SC or AntpMAPOVACD8 SC+CpG on days 0, 10 and
17. Ten days later, mice were challenged with a subcutaneous dose of
2×105 B16-OVA cells resuspended in 100 µl sterile PBS. The
expression of OVA in B16-OVA tumor cells was conﬁrmed by ﬂow
cytometry (data not shown). The subcutaneous growth of the tumor
was monitored by measuring the two perpendicular diameters using
calipers and the results are expressed as the product of the two
perpendicular diameters.
2.7. In vivo maturation
C57BL/6micewere injected i.d. in the footpadwith peptides or LPS
(positive control). 18 h later popliteal lymph nodes were isolated and
pooled (n=4) and stained with CD11c-APC and maturation markers
Fig. 1. Conjugation of Antp to a MAP incorporating the CD8 epitope (OVACD8) of the model antigen ovalbumin.
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(BDCanto, BD Biosciences, USA). Live cells were gated on PI staining
and cells gated on CD11c+hi staining.
2.8. In vivo proliferation
Splenocytes from OT-I mice were isolated and puriﬁed using a T
cell antibody cocktail (rat anti-mouse Gr-1 (RB6–8C5), anti-B220
(RA3–6B2), anti-CD11b (M1/70.15), anti-erythrocyte (TER-119) and
anti-MHC class II (M5/114)) (provided by Dr Mark Wright, Burnet
Institute). T cells were separated using BioMag anti-rat magnetic
beads (Qiagen, Hilden, Germany) (8 beads per cell) at 4 °C for 25 min.
Cells bound to the beads were removed by magnetic attraction and
washed and counted.
Puriﬁed OT-I T cells were resuspended in 0.1%BSA/PBS and labeled
with 25 μM carboxyﬂuorescein succinimidyl ester (CFSE) (Molecular
Probes, Eugene, OR) for 10 min at 37 °C. Labelingwas stoppedwith 5×
volume of ice cold complete RPMI and cells washed extensively in PBS
and CFSE labeling conﬁrmed via ﬂow cytometry. 107 CFSE-labeled OT-
I T cells were then injected intravenously (i.v.) in 200 µl PBS into
C57BL/6 mice immunized 20 h prior i.d. in the base of the tail.
Splenocytes were collected 60 h later and stained with APC-
conjugated anti-CD3 (BD Pharmingen) for 30 min at 4 °C in 2% FCS/
PBS. Cells were then washed and analyzed for co-staining of CD3 and
CFSE by ﬂow cytometry.
2.9. In vivo killing
Splenocytes from naïve C57BL/6 mice were isolated and resus-
pended at 107 cells/ml in serum free RPMI and divided into 2
populations, pulsed or unpulsed. Pulsed splenocytes were incubated
with 1 µg/ml OVACD8 peptide for 1 h at 37 °C. Cells were washed and
resuspended in 0.1% BSA/PBS and labeled with a high concentration
(5 µM) (pulsed splenocytes) or low concentration (0.5 µM) (unpulsed
splenocytes) of CFSE (Molecular Probes, Eugene, OR) respectively for
10 min 37 °C. Labeling was stopped with 5× volume of ice cold
complete RPMI, cells washed extensively in PBS and CFSE labelingconﬁrmed via ﬂow cytometry (data not shown). Peptide-pulsed
5×106 CFSEhigh cells and 5×106 unpulsed CFSElow cells were mixed
and a total of 107 CFSE-labeled cells in 200 µl PBS injected i.v.
into mice immunized 8 days prior. After 20 h splenocytes were
isolated and analyzed by ﬂow cytometry. Speciﬁc lysis was calculated
as: {[1−(ratio CFSElow/CFSEhigh of naïve mice/ratio CFSElow/CFSEhigh
of immunized mice)]×100}.
2.10. MHC class I mechanism studies
DC (2×105 cells) were cultured in complete RPMI media and
incubated for 45 min at 37 °C with the following inhibitors: NaN3
(10 mM) (Sigma, St Louis, MO) and 2-deoxyglucose (10 mM)
(Sigma), amiloride (6 mM) (Sigma), cytochalasin D (10 µg/ml)
(Sigma), dextran sulphate (Progen Industries Ltd, Darra, Australia)
(10 µg/ml), ﬁlipin III (10 ug/ml) (Sigma), ammonium chloride
(200 µM) (Ajax Chemicals, Sydney, Australia), monensin (1 mM)
(Sigma), lactacystin (10 µM) (Calbiochem), brefeldin A (10 µg/ml)
(Sigma), furin inhibitor decRVKR-CMK (10 µM) (Calbiochem), besta-
tin (10 µM) (Sigma) and chloropromazine (10 µg/ml) (Sigma).
AntpMAPOVACD8 SS and AntpMAPOVACD8 SC was added to DC at
5, 25 and 50 µM at 37 °C and added to B3Z T cells as described above.
Inhibitors were not removed from the T cell cultures. To determine if
inhibitors affected T cells, DC pulsed with OVACD8 and inhibitors
were also added to B3Z T cells as controls.
To determine tapasin (TAP) dependence on processing, EL-4 (TAP-
competent) and RMA-S (TAP-deﬁcient) cells (2×105) were pulsed
with 5, 25 and 50 µM peptides at 37 °C for 24 h and T cells added as
described above.
2.11. Statistical analysis
Assays were set up in triplicate. Mean values were compared using
the two-tailed unpaired t-test and ANOVA. Two p-value thresholds
were used for protection and immunogenicity assays: pb0.01 to
indicate a highly signiﬁcant difference, and pb0.05 to indicate a
signiﬁcant difference.
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3.1. AntpMAPOVACD8 conjugates induce speciﬁc T cell responses in vitro
and in vivo
To assess whether MAPOVACD8, AntpMAPOVACD8 SS and AntpMA-
POVACD8SCareprocessedandpresentedbyDC to theTCRofB3Z T cells,
DC were cultured and pulsed with 5 µM of conjugates. DC were
incubated with B3Z T cells for 24 h and the recognition of the OVACD8
epitope on theMHC class Imolecule by its speciﬁc TCRwas assessed via a
colorimetric assay. DC alone was used as a negative control. DC pulsed
with AntpMAPOVACD8 SS and AntpMAPOVACD8 SC at 5 µM induced
presentation toB3ZTcells thatwas signiﬁcantly aboveDCalone(Fig. 2A).Fig. 2. AntpMAPOVACD8 SS and SC stimulate T cells in vitro and in vivo. (A) C57BL/6 DC and
peptide (5 µM) or OVACD8 for 8 h and added to B3Z T cells for 16 h. LacZ activity in B3Z
(560 nm) of culture wells was read after 4 h incubation at 37 °C. Values are representative
AntpMAPOVACD8 SS, AntpMAPOVACD8 SC or MAPOVACD8 via i.d. injection. Number of IFN
spot-forming units (SFU)/5×105 cells. **pb0.01.However DC pulsed with MAPOVACD8 or Antp peptide alone did not
present T cells (Fig. 2A). Thus the conjugation of Antp to MAPOVACD8
allows the uptake, processing and presentation of CD8 T cell epitopes. DC
pulsedwithOVACD8 is surface-loadedandwasusedas apositive control.
The ability of MAPOVACD8, AntpMAPOVACD8 SS and AntpMAPO-
VACD8 SC to induce CD8+ T cell responses in vivo was determined
using an IFN-γ ELISpot assay. C57BL/6 mice were immunized i.d. with
100 µg AntpMAPOVACD8 SS, AntpMAPOVACD8 SC orMAPOVACD8 on
days 0, 10 and 17 and antigen-speciﬁc IFN-γ responses measured
14 days later. Mice immunized with either AntpMAPOVACD8 SS or
AntpMAPOVACD8 SC generated equal IFN-γ secreting cells which
recognized OVACD8 as well as OVA (Fig. 2B, C). The CD4 epitope of
OVA (OVA323–339) was used as a negative control for induction ofwere stimulated with MAPOVACD8, AntpMAPOVACD8 SS, AntpMAPOVACD8 SC Antp
T cells was assayed in total culture lysates with LacZ substrate CPRG. The absorbance
of mean±SEM. (B–D) C57BL/6 mice were injected on day 0, 14 and 17 with 100 µg
-γ secreting cells was analyzed by ELISPOT assay and results are shown as mean±SD
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did not generate IFN-γ secreting cells (Fig. 2D).
3.2. AntpMAPOVACD8 conjugates induce potent in vivo proliferation
and killing
To assess the ability of AntpMAPOVACD8 SS and AntpMAPOVACD8
SC conjugates to induce proliferation of T cells in vivo, we adoptively
transferred CFSE-labeled OT-I splenocytes into mice immunized with
AntpMAPOVACD8 SS or AntpMAPOVACD8 SC. Sixty hours after
injection with OT-I cells similar proliferation levels of OT-I cells
were detected in mice immunized with AntpMAPOVACD8 SS or
AntpMAPOVACD8 SC but not control mice (Fig. 3).
The capacity of mice to generate OVACD8 speciﬁc killing in vivo
following a single immunization was assessed. No OVACD8-speciﬁc
CTL response was detected in the spleen of control mice. In contrast,
strong in vivo lysis was detected when mice were immunized with
either AntpMAPOVACD8 SS (68%) and AntpMAPOVACD8 SC (78%)
(Fig. 4).
3.3. Addition of CpG oligodinucleotides with AntpMAPOVACD8 conjugates
induces protection against B16-OVA tumor cells
Since disulphide-linked and thioether-linked AntpMAPOVACD8
demonstrated similar immunogenicities the ability of mice immunized
with AntpMAPOVACD8 SC to be protected from challenge with OVA-
expressing B16 melanoma tumor cells was investigated. In addition we
also evaluated whether co-administration with the adjuvant CpG could
improve efﬁcacy and enhance anti-tumor immunity. Groups of mice
(n=8) were injected i.d. with PBS, 100 µg AntpMAPOVACD8 SC alone
or 100 µgAntpMAPOVACD8 SC+50 µg CpGondays 0, 10 and 17. Seven
days after immunization mice were challenged subcutaneously with
2×105 B16-OVA tumor cells and tumor growth was monitored.
Pre-immunization of mice with AntpMAPOVACD8 SC did not
prevent B16-OVA tumor growth in any of the experimental groups
(Fig. 5). However, mice immunized with AntpMAPOVACD8 SC with
CpG exhibited signiﬁcantly delayed tumor growth compared to mice
immunized with PBS or AntpMAPOVACD8 SC alone (Fig. 5, pb0.05).
3.4. Maturation of DCs in vivo by AntpMAPOVACD8 conjugates
To understand the mechanism of induction of potent T cell
responses in mice immunized with MAPOVACD8 conjugates, we
assessed the ability of AntpMAPOVACD8 conjugates to induce
maturation of DCs in vivo. C57BL/6 mice were injected i.d. on the
footpads and 18 h later popliteal lymph nodes were removed, cells
stained with the DC marker CD11c and maturation markers (CD40,
CD80, CD86, and MHC class II) were assessed by ﬂow cytometry.Fig. 3.Measurement of CD8+ T cell proliferation in vivo by CFSE dilution. C57BL/6 mice were
puriﬁed CFSE-labeled OT-I T cells were injected i.v. into immunized mice 20 h later. Spleno
cells. Representative histograms from 2 mice are shown.Analysis revealed that AntpMAOVACD8 conjugates do not induce
maturation of DC (Fig. 6).3.5. Uptake of AntpMAPOVACD8 conjugates by DC
There are numerous conﬂicting reports regarding the uptake
mechanisms of CPP [18,19]. It is clear that peptide concentration,
conjugation methods and cell type are all critical factors. To
investigate if AntpMAPOVACD8 SS and AntpMAPOVACD8 SC con-
jugates are taken up by an energy-dependent mechanism in DC, cells
were preincubated with sodium azide and 2-deoxyglucose to deplete
ATP, then pulsed with 5, 25 and 50 µM of AntpMAPOVACD8 SS and
AntpMAPOVACD8 SC and added to B3Z T cells. Presentation of both
AntpMAPOVACD8 SS and AntpMAPOVACD8 SC to B3Z T cells was
completely blocked, thus uptake of both conjugates at varying
concentrations is via energy-dependant endocytosis (Fig. 7).
To further clarify the endocytic uptake pathway inhibitors of
clathrin-mediated and caveolae-mediated endocytosis were assessed.
Chlorpromazine and ﬁlipin III were incubated with DC followed by
pulsing with AntpMAPOVACD8 conjugates for 8 h and presentation to
B3Z T cells. Presentation of AntpMAPOVACD8 SS and SC was inhibited
by N90% at all peptide concentrations by chlorpromazine, demon-
strating uptake is clathrin-dependent. AntpMAPOVACD8 SS presen-
tation was inhibited by 15.8, 99.0 and 99.2% at 5, 25 and 50 µM and
AntpMAPOVACD8 SC was inhibited by 41.7, 95.1 and 97.3% at 5, 25
and 50 µM, respectively by ﬁlipin III (Fig. 7). Thus endocytic uptake for
both SS and SC conjugates is caveolae-dependent at high peptide
concentrations, yet caveolae-independent at low concentrations.
To study the role of macropinocytosis in uptake cytochalasin D, an
inhibitor of contraction of actin-containing microﬁlaments which
prevents phagocytosis and amiloride, which inhibits the Na+/H+
exchange inhibiting phagocytosis and/or macropinocytosis were
used. Following pre incubation with cytochalasin D and amiloride,
DC were pulsed with 5, 25 and 50 µM AntpMAPOVACD8 SS or SC then
presented to B3Z T cells. Presentation of both SS and SC conjugates
was prevented by cytochalasin D. Presentation after amiloride
treatment of AntpMAPOVACD8 SS was inhibited by 81.9, 83.4 and
88.1% at 5, 25 and 50 µM and AntpMAPOVACD8 SC by 83.4, 87.0 and
87.3% at 5, 25 and 50 µM, respectively.
Overall the uptake of AntpMAPOVACD8 SS and SC is via energy-
dependant endocytosis, most likely via phagocytosis and/or macro-
pinocytosis. At a low peptide concentrations uptake is also via
negatively charged receptors as demonstrated by inhibition with
dextran sulphate for both AntpMAPOVACD8 SS and AntpMAPOVACD8
SC but not for higher concentrations (Fig. 7). Endocytosis is clathrin
and caveolae-dependent however at low concentrations uptake is
caveolae-independent (Fig. 6). In all experiments, DC pulsed with
OVACD8 in the presence or absence of biochemical inhibitorimmunized i.d. with (A) PBS, (B) AntpMAPOVACD8 SS or (C) AntpMAPOVACD8 SC and
cytes were subsequently assessed via ﬂow cytometry for CFSE dilution, gated on CD3 T
Fig. 4. In vivo OVACD8-speciﬁc lysis. C57BL/6 mice were immunized i.d. with PBS, AntpMAPOVACD8 SS or AntpMAPOVACD8 SC. (A) The percentage of the OVACD8 speciﬁc lysis was
determined 8 days after immunization calculated as: {[1−(CFSElow/CFSEhigh of naïve mice/ratio CFSElow/CFSEhigh of immunized mice)]×100}. Representative histograms are
shown. (B) Data is presented as mean % of killing±SEM. **pb0.01.
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3.6. Presentation and processing of AntpMAPOVACD8 conjugates by
TAP-independent MHC class I pathway
The role of endosomal processing was investigated using chloro-
quine and ammonium chloride, which prevent acidiﬁcation of
endosomes and monensin, a sodium/potassium proton ionophore
which interferes with Golgi transport, acidiﬁcation of intracellularFig. 5. C57BL/6 mice preimmunized on days 0, 10 and 17 with PBS, AntpMAPOVACD8
SC or AntpMAPOVACD8 SC+CpG then inoculated subcutaneously 7 days after ﬁnal
immunization with 2×105 B16-OVA melanoma cells into the abdomen and tumor
growth recorded. Data presented 17 days post tumor inoculation.*pb0.05.compartments and blocks protein transfer from endosomes to
lysosomes. Following pre incubation of chloroquine/ammonium
chloride or monensin, DC were pulsed with 5, 25 and 50 µM
AntpMAPOVACD8 SS or SC then presented to B3Z T cells. Presentation
was inhibited at all peptide concentrations following chloroquine/
ammonium chloride ormonensin treatment (Fig. 8A–B). This suggests
that both AntpMAPOVACD8 SS and SC conjugates are processed via
the endosome and lysosome. In all experiments, DC pulsed with
OVACD8 in the presence of inhibitor or the absence of inhibitor
demonstrated that the inhibitor did not have any effects on the T cells
(data not shown). We further investigated the TAP dependence of
MHC class I presentation using RMA-S cells, deﬁcient in TAP, pulsed
with AntpMAPOVACD8 SS or AntpMAPOVACD8 SC for 1 h and adding
to B3Z T cells. EL-4 cells are TAP-competent and were used as a
positive control for the experiment. RMA-S pulsed with AntpMAPO-
VACD8 SS or SC equally presented to B3Z T cells above background
responses (Fig. 8C). These results indicate that AntpMAPOVACD8
conjugates at all concentrations are processed and presented by MHC
class I molecules via the endosomes and lysosome in a TAP-
independent mechanism.3.7. Proteolysis and peptide loading of AntpMAPOVACD8 conjugates
Presentation of epitopes on MHC class I molecules can be achieved
via degradation in the proteasomes. To examine the processing of
AntpMAPOVACD8 conjugates by proteasomes DC were preincubated
with lactacystin, an inhibitor of proteasomes. Lactacystin had no effect
on the presentation of AntpMAPOVACD8 SS or SC at 5, 25 or 50 µM,
thus conjugates are processed and presented by DC without the
requirement for proteasomes (Fig. 9). To examine the role amino-
peptidase in the ER and furin endopeptidases in the trans-Golgi, the
inhibitors bestatin and furin inhibitor decRVKR-CMK were added to
DCs prior to pulsing with AntpMAOVACD8 conjugates. Neither
bestatin nor the furin inhibitor decRVKR-CMK inhibited of presenta-
tion to B3Z T cells at any peptide concentration.
Fig. 6. In vivoDCmaturation by AntpMAPOVACD8 conjugates. C57BL/6 mice were injected i.d. in the footpadwith AntpMAPOVACD8 SS or AntpMAPOVACD8 SC at 100 µg per mouse.
18 h later popliteal LN were isolated and stained with the DC marker CD11c and maturation markers (CD40, CD80, CD86, and MHC class II) assessed by ﬂow cytometry.
Representative histogram plots are shown (n=3). Mice injected with LPS were used as positive controls.
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synthesized MHC class I and II molecules between ER and Golgi
complex, was pre incubated with DC (Fig. 8). Presentation of
AntpMAPOVACD8 conjugates at 5, 25 and 50 µM was prevented,Fig. 7. Uptake and processing pathways of AntpMAPOVACD8 conjugates. In vitro grown DC
azide/2-deoxyglucose (10 mM), cytochalasin D (10 µg/ml), amiloride (6 µm), dextran sulph
incubated with (A) AntpMAPOVACD8 SS and (B) AntpMAPOVACD8 SC conjugates at 5, 25
assessed by B3Z assay. Values are representative of mean±SEM.thus it is clear that both AntpMAPOVACD8 SS and SC are not degraded
in the proteasome and that furin endopeptidase in the trans-Golgi and
aminopeptidases in the ER do not contribute to further trimming. In
all experiments, DC pulsed with OVACD8 in the presence of inhibitors were incubated for 45 min with biochemical inhibitors of uptake pathways (sodium
ate (50 µg/ml), chloropromazine (10 µg/ml) and ﬁlipin III (10 µg/ml)). Cells were then
and 50 µM. DCs were added to antigen-speciﬁc CD8 T cell clones and stimulation was
Fig. 8. Presentation and processing of AntpMAPOVACD8 conjugates. In vitro grown DCs were incubated for 45 min with inhibitors chloroquine/NH4Cl (200 µM), and monensin
(1000 µM). Cells were then incubated with (A) AntpMAPOVACD8 SS and (B) AntpMAPOVACD8 SC conjugates at 5, 25 and 50 µM. DCs were added to antigen-speciﬁc CD8 T cell
clones and stimulation was assessed by B3Z assay. (C) EL-4 and RMA-S cells were stimulated with AntpMAPOVACD8 SS and SC (5 µM) or OVACD8 for 8 h and added to antigen-
speciﬁc CD8 T cell clones and stimulation was assessed by B3Z assay. Values are representative of mean±SEM.
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have any effects on the T cells (data not shown).
4. Discussion
The objective of immunization strategies for cancer is to facilitate
the presentation of antigenic epitopes by APCs to T cells and generate
a potent immune response. For generation of effector CTL, exogenous
antigens must enter the cross presentation pathway and be presented
to CD8 T cells in the context of MHC Class I molecules. There is now a
wealth of evidence demonstrating the superior cellular delivery of
tumor associated peptides or proteins by conjugation to CPPs,
ultimately leading to the generation of potent immune responses
[4,9,20–22].
It is now clear that the delivery of CD8 and CD4 T cell epitopes is
obligatory for the generation of long term immunity [23]. We have
previously demonstrated that Antp tandemly linked to OVACD8 was
rapidly internalized into the cytoplasm of macrophages, induced
peptide speciﬁc T cells and protected mice against a subsequent
tumor challenge [9]. Moreover both Antp and TAT have been used to
deliver to CD8 and CD4 epitopes from OVA generating CTL and Th
responses and an anti-tumor immunity [13]. However due to
limitations in the synthesis of long linear peptides, the design of
branched MAP allow for the inclusion of a greater number of tumor
epitopes which would be advantageous for cancer vaccines [11]. The
current study validates this approach using a MAP incorporating 4
identical OVACD8 epitopes. A similar approach can be used to deliverMAPs incorporating multiple CD8 and CD4 epitopes from the same or
different antigen.
We have now extended on our Antp linear peptide studies to
investigate the ability of Antp to deliver a 4 asymmetric branched
peptide incorporating OVACD8 (MAPOVACD8) to APCs. We reveal
that penetratin (Antp) linked to the MAPOVACD8 either by a disulﬁde
(SS) or thioether (SC) linkage is taken up in vitro by DC and enters the
cross presentation pathways for MHC class I loading. Moreover mice
immunized with AntpMAPOVACD8 SS or AntpMAPOVACD8 SC
induced strong CD8+ speciﬁc IFN-γ responses shown by ELISpot
assay. Whereas the MAPOVACD8 construct without the Antp
internalizing sequence is not presented by MHC Class I molecules
nor generates antigen-speciﬁc IFN-γ response in vivo. Mice immu-
nized with AntpMAPOVACD8 SS or AntpMAPOVACD8 SC showed
strong in vivo proliferation. Likewise mice immunized with AntpMA-
POVACD8 SS or AntpMAPOVACD8 SC generated potent and compa-
rable OVACD8 speciﬁc in vivo lysis.
Our results showing the capacity of CPP to induce a superior
immune response via enhanced delivery and presentation is sup-
ported by Shibagaki and Udey [22] who compared the immunoge-
nicity of OVA with and without the inclusion of the 11-mer HIV TAT
transduction domain (YGRKKRRQRRR). Recombinant TAT-OVA was
efﬁciently transduced into DC and processed by proteasome-depen-
dent pathway for MHC class I restricted presentation to CTL [22].
Furthermore, subcutaneous immunization of TAT-OVA transduced DC
induced antigen-speciﬁc CTL and Th and protected against a lethal
dose of OVA-expressing tumor cell line, EG.7. In contrast, OVA failed to
Fig. 9. Proteolysis and peptide loading of AntpMAPOVACD8 conjugates. In vitro grown DCs were incubated for 45 min with biochemical inhibitors (furin inhibitor (10 µM), bestatin
(10 µM), brefeldin (10 µg/ml) and lactacystin (10 µM)). Cells were then incubated with (A) AntpMAPOVACD8 SS and (B) AntpMAPOVACD8 SC conjugates at 5, 25 and 50 µM. DCs
were added to antigen-speciﬁc CD8 T cell clones and stimulation was assessed by B3Z assay. Values are representative of mean±SEM.
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afford the same degree of protection as TAT-OVA DC [22].
Maturation of DCs involves up-regulation of co-stimulatory
molecules (e.g. CD40, CD80 and CD86) and pro-inﬂammatory
cytokines (e.g. interleukin (IL)-12, IL-4) for optimal Th1 or Th2 cell
priming [24]. However following in vivo injection of either AntpMA-
POVACD8 SS or AntpMAPOVACD8 SS, isolated lymph node DC did not
mature and revealed no change in expression of co-stimulatory
molecules including CD40, CD80, CD86 and MHC Class II. Thus the
delayed anti-tumor response promoted by the adjuvant CpG may in
part be explained by the addition of a danger signal and generation of
a more robust T cell proliferation response [7]. In our previous studies
we demonstrated that a linear fusion peptide incorporating Antp and
the OVA CD8 epitope SIINFEKL (AntpOVACD8) was able to completely
protect mice from a lethal B16-OVA tumor challenge [9,25]. However,
in the current study utilizing a branched AntpMAPOVACD8 signiﬁcant
tumor inhibition was only apparent when used in combination with
CpG. Amajor difference between AntpOVACD8 and AntpMAPOVACD8
is the purity of peptide. Unlike AntpOVACD8 linear peptide synthe-
sized with purities of greater than 95%, MAP peptide purity range
from 60 to 70%. Therefore it is possible that the immunogen
AntpMAPOVACD8 is not as potent as AntpOVACD8 and may require
higher doses than 100 µg to be more efﬁcacious. In order to overcome
the purity issues we are now investigating an alternative synthesis of
MAP based on native chemical ligation methods [26,27].
The aim of utilizing CPPs for cancer vaccines is the targeting to
intracellular compartments to generate a therapeutic response. The
mechanism of internalization of CPPs has gained considerable
attention in recent years with varied and conﬂicting results, arising
due to different experimental conditions [28]. The endocytic path-
ways, macropinocytosis, clathrin-mediated and caveolae/lipid-raft
mediated endocytosis, along with interaction of polycationic CPP with
negatively charged heparin sulphate proteoglycans are widely
implicated in the uptake of CPP [18,29]. We reveal that uptake of
AntpMAPOVACD8 SS and AntpMAPOVACD8 SC is via energy-dependant endocytosis. Endocytosis can occur via clathrin-mediated
endocytosis, macropinocytosis, caveolae-mediated endocytosis, cla-
thrin-caveolae-independent endocytosis pathways depending on the
peptide concentration of the CPP. The majority AntpMAPOVACD8
conjugates are taken up by DC via phagocytosis and/or macropino-
cytosis and using the inhibitor chlorpromazine we show uptake to
occur via clathrin-mediated endocytosis.
No difference between uptake pathways of the disulﬁde or
thioether linked AntpMAOVACD8 construct was seen. However in
agreement with others peptide concentration appears to alter the
uptake pathway. At low concentrations AntpMAPOVACD8 SS and
AntpMAPOVACD8 SC binds to negatively charged receptors, whereas
at higher concentrations uptake is independent of negatively charge
receptors. Moreover uptake at high concentrations (25 and 50 µM) is
caveolae-dependent whereas at 5 µM uptake occurs via caveolae-
independent uptake pathway. Both AntpMAPOVACD8 SS and
AntpMAPOVACD8 SC are equally inhibited by dextran sulphate, a
competitor for negative charges however, uptake of AntpMAPO-
VACD8 SC is predominantly via the caveolar independent pathway.
Studies on the subsequent intracellular trafﬁcking routes of
AntpMAPOVACD8 conjugates show proteasome independent proces-
sing via the endosomes and lysosome for presentation by MHC Class I
molecules with further trimming by furin endopeptidase in the trans-
Golgi or by aminopeptidases not required. In addition access to the ER
is TAP-independent, as also shown with TAT-OVACD8 and AntpO-
VACD8 processing studies [9,30]. Studies using the TAT peptide linked
to OVACD8 also show a Golgi–ER independent pathway, although
linking CPP and the antigen using either the carboxyl or amino
terminal end changes the intracellular processing pathways. Linking
OVACD8 to the amino terminal (OVACD8-TAT) requires furin
endopeptidases in the trans-Golgi for processing. Yet presentation
of OVACD8 linked to the carboxyl terminal (TAT-OVACD8) is furin
independent [30].
In summary we have shown that the linking of the CPP Antp to an
asymmetric 4 branched MAP incorporating the H-2Kb CD8 eight-mer
2295N.A. Brooks et al. / Biochimica et Biophysica Acta 1798 (2010) 2286–2295epitope OVACD8 promotes the uptake and cross presentation and
subsequent proliferation and generation antigen-speciﬁc T cells. Thus
Antp represents a proﬁcient means to deliver branched MAP to
generate immunity enabling application with polytope peptides
scaffolds. Moreover immunization of antigen with CpG signiﬁcantly
delays tumor growth. We also show that the uptake mechanism of
AntpMAPOVACD8 constructs is dose-dependent and neither uptake
nor intracellular processing is altered by the type of chemical linkage.
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